164 related articles for article (PubMed ID: 27827395)
1. Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer.
Devetzi M; Kosmidou V; Vlassi M; Perysinakis I; Aggeli C; Choreftaki T; Zografos GN; Pintzas A
Sci Rep; 2016 Nov; 6():36532. PubMed ID: 27827395
[TBL] [Abstract][Full Text] [Related]
2. Noxa upregulation and 5-gene apoptotic biomarker panel in colorectal cancer.
Kosmidou V; Vlassi M; Anagiotos K; Raftopoulou S; Kalogerakou E; Skarmalioraki S; Aggeli C; Choreftaki T; Zografos G; Pintzas A
Eur J Clin Invest; 2021 Jan; 51(1):e13353. PubMed ID: 32682341
[TBL] [Abstract][Full Text] [Related]
3. Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK-mediated DR5 regulation in colorectal cancer.
Kim SL; Min IS; Park YR; Lee ST; Kim SW
Int J Oncol; 2018 Dec; 53(6):2789-2799. PubMed ID: 30221676
[TBL] [Abstract][Full Text] [Related]
4. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
Chen X; Kandasamy K; Srivastava RK
Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
[TBL] [Abstract][Full Text] [Related]
5. Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis.
Yoshida T; Shiraishi T; Horinaka M; Nakata S; Yasuda T; Goda AE; Wakada M; Mizutani Y; Miki T; Nishikawa A; Sakai T
Cancer Sci; 2007 Sep; 98(9):1417-23. PubMed ID: 17645780
[TBL] [Abstract][Full Text] [Related]
6. TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.
Nahacka Z; Svadlenka J; Peterka M; Ksandrova M; Benesova S; Neuzil J; Andera L
Biochim Biophys Acta Mol Cell Res; 2018 Mar; 1865(3):522-531. PubMed ID: 29278689
[TBL] [Abstract][Full Text] [Related]
7. Regulation of TRAIL receptor expression by β-catenin in colorectal tumours.
Jalving M; Heijink DM; Koornstra JJ; Boersma-van Ek W; Zwart N; Wesseling J; Sluiter WJ; de Vries EG; Kleibeuker JH; de Jong S
Carcinogenesis; 2014 May; 35(5):1092-9. PubMed ID: 24379239
[TBL] [Abstract][Full Text] [Related]
8. RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer.
Khawaja H; Campbell A; Roberts JZ; Javadi A; O'Reilly P; McArt D; Allen WL; Majkut J; Rehm M; Bardelli A; Di Nicolantonio F; Scott CJ; Kennedy R; Vitale N; Harrison T; Sansom OJ; Longley DB; Evergren E; Van Schaeybroeck S
Cell Death Dis; 2020 Oct; 11(10):930. PubMed ID: 33122623
[TBL] [Abstract][Full Text] [Related]
9. Casticin, a flavonoid, potentiates TRAIL-induced apoptosis through modulation of anti-apoptotic proteins and death receptor 5 in colon cancer cells.
Tang SY; Zhong MZ; Yuan GJ; Hou SP; Yin LL; Jiang H; Yu ZΥ
Oncol Rep; 2013 Feb; 29(2):474-80. PubMed ID: 23135489
[TBL] [Abstract][Full Text] [Related]
10. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
11. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
Yan S; Qu X; Xu C; Zhu Z; Zhang L; Xu L; Song N; Teng Y; Liu Y
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1279-89. PubMed ID: 22447040
[TBL] [Abstract][Full Text] [Related]
13. Tetrandrine (TET) Induces Death Receptors Apo Trail R1 (DR4) and Apo Trail R2 (DR5) and Sensitizes Prostate Cancer Cells to TRAIL-Induced Apoptosis.
Shishodia G; Koul S; Dong Q; Koul HK
Mol Cancer Ther; 2018 Jun; 17(6):1217-1228. PubMed ID: 29549167
[TBL] [Abstract][Full Text] [Related]
14. DR5 receptor mediates anoikis in human colorectal carcinoma cell lines.
Laguinge LM; Samara RN; Wang W; El-Deiry WS; Corner G; Augenlicht L; Mishra L; Jessup JM
Cancer Res; 2008 Feb; 68(3):909-17. PubMed ID: 18245494
[TBL] [Abstract][Full Text] [Related]
15. Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL.
Sung B; Ravindran J; Prasad S; Pandey MK; Aggarwal BB
J Biol Chem; 2010 Nov; 285(46):35418-27. PubMed ID: 20837473
[TBL] [Abstract][Full Text] [Related]
16. Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin.
Tse AK; Cao HH; Cheng CY; Kwan HY; Yu H; Fong WF; Yu ZL
J Invest Dermatol; 2014 May; 134(5):1397-1407. PubMed ID: 24213373
[TBL] [Abstract][Full Text] [Related]
17. miR-128 Targets the SIRT1/ROS/DR5 Pathway to Sensitize Colorectal Cancer to TRAIL-Induced Apoptosis.
Lian B; Yang D; Liu Y; Shi G; Li J; Yan X; Jin K; Liu X; Zhao J; Shang W; Zhang R
Cell Physiol Biochem; 2018; 49(6):2151-2162. PubMed ID: 30257253
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
Hassanzadeh A; Farshdousti Hagh M; Alivand MR; Akbari AAM; Shams Asenjan K; Saraei R; Solali S
J Cell Physiol; 2018 Oct; 233(10):6470-6485. PubMed ID: 29741767
[TBL] [Abstract][Full Text] [Related]
19. Targeting the glyoxalase pathway enhances TRAIL efficacy in cancer cells by downregulating the expression of antiapoptotic molecules.
Taniguchi H; Horinaka M; Yoshida T; Yano K; Goda AE; Yasuda S; Wakada M; Sakai T
Mol Cancer Ther; 2012 Oct; 11(10):2294-300. PubMed ID: 22784708
[TBL] [Abstract][Full Text] [Related]
20. Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.
Jang JY; Jeon YK; Choi Y; Kim CW
Mol Cancer; 2010 Sep; 9():262. PubMed ID: 20875141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
